Malignant Salivary Gland Neoplasm — Trials

Malignant Salivary Gland Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 63
Recruiting: 32
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 21.4%
Trials / 1,000 deaths: 56.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 51–63 of 63 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00458978	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer	completed	Phase 2	6	National Cancer Institute (NCI)NIH	1	May 5, 2015	clinicaltrials
NCT00114283	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	completed	Phase 2	30	National Cancer Institute (NCI)NIH	1	Apr 15, 2015	clinicaltrials